Artur Slupianek

Artur Slupianek

UNVERIFIED PROFILE

Are you Artur Slupianek?   Register this Author

Register author
Artur Slupianek

Artur Slupianek

Publications by authors named "Artur Slupianek"

Are you Artur Slupianek?   Register this Author

24Publications

514Reads

12Profile Views

Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Blood 2011 Jul 7;118(4):1062-8. Epub 2011 Jun 7.

Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-09-307256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148158PMC
July 2011

BCR/ABL stimulates WRN to promote survival and genomic instability.

Cancer Res 2011 Feb 1;71(3):842-51. Epub 2010 Dec 1.

Department of Microbiology and Immunology, School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-1066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3032814PMC
February 2011

The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells.

J Cell Physiol 2010 Aug;224(2):369-75

Department of Microbiology & Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.22132DOI Listing
August 2010

[Uracil-DNA glycosylases].

Postepy Biochem 2008 ;54(4):362-70

Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, USA.

View Article

Download full-text PDF

Source
March 2009

Brain tumor formation in tuberous sclerosis depends on Erk activation.

Neuromolecular Med 2007 ;9(2):117-27

Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, and Department of Pathology, The Children's Memorial Health Institute, Warsaw, Poland.

View Article

Download full-text PDF

Source
December 2007

[The role of oncogenic tyrosine kinases in the cellular response to anticancer therapy].

Postepy Hig Med Dosw (Online) 2007 Dec 14;61:819-27. Epub 2007 Dec 14.

Katedra Mikrobiologii i Immunologii, Temple University School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
December 2007

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.

Cell Cycle 2006 May 1;5(9):994-1000. Epub 2006 May 1.

Department of Microbiology and Immunology, Temple University, Philadelphia, Pennsylvania 19140, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.5.9.2722DOI Listing
May 2006

BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

DNA Repair (Amst) 2006 Feb 16;5(2):243-50. Epub 2005 Nov 16.

Center for Biotechnology, College of Science and Technology, Temple University, Bio-Life Sciences Building, Room 419, 1900 N. 12th Street, Philadelphia, PA 19122, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2005.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856314PMC
February 2006

BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin.

Oncogene 2005 Jun;24(24):3914-22

Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1208545
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1208545DOI Listing
June 2005

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Blood 2004 Dec 10;104(12):3746-53. Epub 2004 Aug 10.

Center for Biotechnology, College of Science and Technology, Temple University, Bio-Life Sciences Bldg, Rm 419, 1900 N 12th St, Philadelphia, PA 19122, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/content/104/12/3746.full.pdf
Web Search
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-05-19
Publisher Site
http://dx.doi.org/10.1182/blood-2004-05-1941DOI Listing
December 2004

NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner.

Exp Hematol 2004 Dec;32(12):1265-71

College of Science and Technology, Center for Biotechnology, Temple University, Philadelphia, Pa. 19008, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2004.11.002DOI Listing
December 2004

BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.

Cell Cycle 2004 Nov 10;3(11):1463-72. Epub 2004 Nov 10.

Molecular Carcinogenesis Section, Center of Biotechnology, College of Science and Technology, Temple University, 1900 N. 12th Street, Philadelphia, Pennsylvania 19122, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.3.11.1229DOI Listing
November 2004

TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.

Anticancer Drugs 2003 Sep;14(8):625-31

Department of Molecular Genetics University of Lodz, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200309000-00007DOI Listing
September 2003

Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

Leuk Res 2003 Mar;27(3):267-73

Department of Clinical Cytobiology, Medical Center for Postgraduate Education, 01-813 Warszawa, Marymoncka 99, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0145-2126(02)00163-7DOI Listing
March 2003

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

EMBO J 2002 Nov;21(21):5766-74

Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC131059PMC
http://dx.doi.org/10.1093/emboj/cdf562DOI Listing
November 2002

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

Oncogene 2002 Aug;21(38):5868-76

Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania 19122, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1205724
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1205724DOI Listing
August 2002